CTMX
CytomX Therapeutics, Inc.
There isn't enough reported data to score CTMX yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CTMX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Unavailable |
CTMX's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CTMX PE Valuation
CTMX has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CTMX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect CTMX's losses to grow, with revenue declining. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CTMX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.61 | -253% |
| Q2 2026 | -$0.61 | -209% |
| Q1 2026 | -$0.52 | -208% |
| Q4 2025 | -$0.15 | -139% |
| Q3 2025 | $0.40 | +122% |
| Q2 2025 | $0.56 | +273% |
| Q1 2025 | $0.48 | +129% |
| Q4 2024 | $0.38 | +$0.39 |
CTMX has swung to a loss: it lost $0.61 per share over the past year, after a profit the year before.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
CTMX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.7M | -72% |
| Q2 2026 | $1.4M | -92% |
| Q1 2026 | $10.3M | -80% |
| Q4 2025 | $663K | -98% |
| Q3 2025 | $6M | -82% |
| Q2 2025 | $18.7M | -26% |
| Q1 2025 | $50.9M | +23% |
| Q4 2024 | $38.1M | +43% |
CTMX's revenue has slid since its 2025 peak: $2M last quarter, down 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1392% | -1128 points |
| Q2 2026 | -1677% | -1670 points |
| Q1 2026 | -192% | -236 points |
| Q4 2025 | -4213% | -4259 points |
| Q3 2025 | -264% | -277 points |
| Q2 2025 | -6.9% | +27 points |
| Q1 2025 | 44% | +16 points |
| Q4 2024 | 46% | +49 points |
CTMX's operating margin was −1392% last quarter, down 1128 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over CTMX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over CTMX on profitability, with a higher operating margin.
CTMX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $16.1M | +$31.5M |
| Q2 2026 | -$18.1M | -$2.3M |
| Q1 2026 | -$25.5M | -$4.4M |
| Q4 2025 | -$23.4M | -$3.5M |
| Q3 2025 | -$15.4M | +$5.3M |
| Q2 2025 | -$15.8M | +$3.9M |
| Q1 2025 | -$21.2M | +$5M |
| Q4 2024 | -$20M | +$2.2M |
CTMX has burned cash in almost every quarter: −$51M over the past year, against −$72M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over CTMX on cash generation, producing positive trailing cash flow while its opponent burns cash.
CTMX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +167K shares |
| 1 year | +33% | +54.1M shares |
| 3 years | +171% | +138M shares |
| 5 years | +236% | +154M shares |
| Available history | +383% | +174M shares |
CTMX has 219M diluted shares, up 33% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CTMX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CTMX Net Leverage
CTMX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CTMX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.8 | Neutral |
| Stochastic | 7.3 | Oversold |
CTMX's weekly RSI is 31 (neutral) and its Stochastic is 7 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CTMX PE vs Healthcare Sector
| Metric | CTMX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CTMX has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CTMX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.38 | 14% below |
| 20 week MA | $2.98 | 32% below |
| 50 week MA | $3.82 | 47% below |
| 100 week MA | $2.87 | 29% below |
| 200 week MA | $2.23 | 8.5% below |
CTMX is in a downtrend: it's below all five of its weekly moving averages, and 8.5% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CTMX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.54 | $7.42 | -13% |
| 2021 | $7.42 | $4.22 | -43% |
| 2022 | $4.22 | $1.55 | -63% |
| 2023 | $1.55 | $1.55 | 0% |
| 2024 | $1.55 | $1.07 | -31% |
| 2025 | $1.07 | $4.39 | +310% |
| 2026 YTD | $4.39 | $2.04 | -54% |
CTMX's yearly returns have swung widely, from +310% in 2025 to −63% in 2022. It's down 54% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over CTMX on returns for 2026, with the stronger performance.